Ray Co., Ltd. (228670.KQ)
KRW 6250.0
(-2.5%)
KRW 6250.0
(-2.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.14 Billion KRW | -126.97% |
| 2022 | 7.95 Billion KRW | 62435.35% |
| 2021 | -12.76 Million KRW | -100.16% |
| 2020 | 7.9 Billion KRW | -31.6% |
| 2019 | 11.55 Billion KRW | 120.04% |
| 2018 | 5.25 Billion KRW | 354.98% |
| 2017 | 1.15 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.16 Billion KRW | -24.05% |
| 2024 Q2 | -16.76 Billion KRW | -224.41% |
| 2023 Q3 | 3.55 Billion KRW | 167.06% |
| 2023 Q4 | -4.16 Billion KRW | -217.26% |
| 2023 FY | -2.14 Billion KRW | -126.97% |
| 2023 Q2 | 1.33 Billion KRW | 146.47% |
| 2023 Q1 | -2.86 Billion KRW | -152.09% |
| 2022 Q2 | 215.45 Million KRW | 185.14% |
| 2022 FY | 7.95 Billion KRW | 62435.35% |
| 2022 Q4 | 5.49 Billion KRW | 120.16% |
| 2022 Q3 | 2.49 Billion KRW | 1058.95% |
| 2022 Q1 | -253.07 Million KRW | 96.87% |
| 2021 FY | -12.76 Million KRW | -100.16% |
| 2021 Q4 | -8.08 Billion KRW | -259.39% |
| 2021 Q3 | 5.07 Billion KRW | 0.0% |
| 2020 FY | 7.9 Billion KRW | -31.6% |
| 2019 FY | 11.55 Billion KRW | 120.04% |
| 2018 FY | 5.25 Billion KRW | 354.98% |
| 2017 FY | 1.15 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 116.43 Billion KRW | 101.843% |
| InBody Co.,Ltd | 36.72 Billion KRW | 105.845% |
| Curexo Inc. | -4.85 Billion KRW | 55.801% |
| Seegene, Inc. | 669.01 Million KRW | 420.819% |
| i-SENS, Inc. | 3.7 Billion KRW | 157.867% |
| Gencurix Inc. | -19.26 Billion KRW | 88.856% |
| Sugentech Inc. | -17.23 Billion KRW | 87.549% |
| L&C Bio Co., Ltd | 48.36 Billion KRW | 104.438% |